Shearman & Sterling advised the underwriters of PROCEPT BioRobotics Corporation’s follow-on offering of 5,085,494 shares of common stock at a public offering price of $33.92 per share, resulting in gross proceeds to the Company of approximately $172.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. The 5,085,494 shares included 663,325 shares issued pursuant to the underwriters’ option to purchase additional shares.

BofA Securities, Piper Sandler and TD Cowen acted as joint book-running managers for the offering and Truist Securities acted as co-manager.

PROCEPT BioRobotics Corporation is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, with an initial focus on treating benign prostatic hyperplasia.

The Team